These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 9329573

  • 1. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T, Schürenkämper P, Minguillon C, Lichtenegger W.
    Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
    [Abstract] [Full Text] [Related]

  • 2. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
    Ebeling FC, Schmitt UM, Untch M, Nagel D, Fateh-Moghadam A, Stieber P, Seidel D.
    Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
    [Abstract] [Full Text] [Related]

  • 3. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R.
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [Abstract] [Full Text] [Related]

  • 4. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
    Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M.
    Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma.
    Reiter W, Stieber P, Reuter C, Nagel D, Cramer C, Pahl H, Fateh-Moghadam A.
    Anticancer Res; 1997; 17(4B):2903-6. PubMed ID: 9329559
    [Abstract] [Full Text] [Related]

  • 6. The serum tumor marker M3/M21 in the follow-up of breast cancer patients.
    Tempfer C, Hanzal E, Zeillinger R, Koelbl H, Dadak C, Kainz C.
    Anticancer Res; 1996; 16(5B):3049-52. PubMed ID: 8920765
    [Abstract] [Full Text] [Related]

  • 7. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrari P, Anselmi L, Conte M, Berti P, Miccoli P.
    BMC Cancer; 2006 Nov 20; 6():269. PubMed ID: 17116247
    [Abstract] [Full Text] [Related]

  • 8. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M, Hippeläinen M, Kettunen J, Salmela E, Penttilä I, Alhava E.
    Anticancer Res; 1994 Nov 20; 14(2B):699-703. PubMed ID: 8010729
    [Abstract] [Full Text] [Related]

  • 9. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR, Beason KL, Bryant S, Johnson JT, Jackson M, Wilson C, Holifield K, Vincent C, Hall M.
    Biomed Sci Instrum; 2003 Nov 20; 39():408-14. PubMed ID: 12724928
    [Abstract] [Full Text] [Related]

  • 10. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
    Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Munoz M, Farrus B, Ballesta AM.
    Anticancer Res; 2003 Nov 20; 23(2A):1035-41. PubMed ID: 12820344
    [Abstract] [Full Text] [Related]

  • 11. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
    Hu XC, Day W, Jones B, Loo WT, Chow LW.
    Anticancer Res; 2002 Nov 20; 22(3):1865-8. PubMed ID: 12168883
    [Abstract] [Full Text] [Related]

  • 12. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
    Lauro S, Trasatti L, Bordin F, Lanzetta G, Bria E, Gelibter A, Reale MG, Vecchione A.
    Anticancer Res; 1999 Nov 20; 19(4C):3511-5. PubMed ID: 10629644
    [Abstract] [Full Text] [Related]

  • 13. [Is follow-up of breast cancer with CEA and CA 15-3 justified?].
    Fritsche E, Benz J.
    Helv Chir Acta; 1992 May 20; 59(1):225-9. PubMed ID: 1526832
    [Abstract] [Full Text] [Related]

  • 14. Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors.
    Lumachi F, Brandes AA, Ermani M, Bruno G, Boccagni P.
    Anticancer Res; 2000 May 20; 20(6C):4751-5. PubMed ID: 11205212
    [Abstract] [Full Text] [Related]

  • 15. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
    Findeisen R, Albrecht S, Richter B, Deutschmann K, Zimmermann T, Distler W.
    Luminescence; 2000 May 20; 15(5):283-9. PubMed ID: 11038485
    [Abstract] [Full Text] [Related]

  • 16. [Tumor markers in the diagnosis and prognosis of breast cancer].
    Seliuzhitskiĭ IV, Skvortsov SV, Lytsar BN, Khomenko LP.
    Klin Med (Mosk); 1993 May 20; 71(2):25-7. PubMed ID: 8046917
    [Abstract] [Full Text] [Related]

  • 17. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M, Kataja V, Hämäläinen E, Kosma VM, Penttilä I, Alhava E.
    Anticancer Res; 1997 May 20; 17(2B):1231-4. PubMed ID: 9137478
    [Abstract] [Full Text] [Related]

  • 18. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
    Eskelinen M, Tikanoja S, Brown J.
    Anticancer Res; 1990 May 20; 10(4):959-62. PubMed ID: 2382995
    [Abstract] [Full Text] [Related]

  • 19. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
    Lumachi F, Brandes AA, Boccagni P, Polistina F, Favia G, D'Amico DF.
    Anticancer Res; 1999 May 20; 19(5C):4485-9. PubMed ID: 10650797
    [Abstract] [Full Text] [Related]

  • 20. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
    Blijlevens NM, Oosterhuis WP, Oosten HR, Mulder NH.
    Anticancer Res; 1995 May 20; 15(6B):2711-6. PubMed ID: 8669851
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.